The Golden Era Of GLP-1 Drugs

This session provides an in-depth look at glucagon-like peptide-1 (GLP-1) agonists, exploring their current applications and future implications for healthcare, the economy, and society. Primarily used to manage blood sugar levels in individuals with Type 2 diabetes, GLP-1 agonists also aid in weight management. Beyond these key functions, they offer several additional benefits, including:

• Lowering blood pressure
• Improving lipid profiles
• Enhancing fatty liver disease outcomes
• Reducing the risk of heart and kidney diseases
• Delaying the progression of diabetes-related nephropathy

As the market for GLP-1 drugs continues to expand, understanding their diverse applications, potential risks, and economic effects is vital for professionals in the pharmaceutical and healthcare sectors.

What You Will Learn:

• The history and significance of GLP-1 receptor antagonists in diabetes treatment
• The potential of GLP-1 drugs for addressing obesity and other major health issues
• How GLP-1 drugs interact with various organ systems
• The projected economic impact of GLP-1 therapies

Presented by Dr. Gaetano Morelli, MD
Dr. Morelli serves as Chief Medical Officer at Altasciences and is a recognized expert in internal medicine and gastroenterology with over 30 years of clinical experience. Since joining Altasciences in 2017, he has contributed to complex studies as a medical advisor and consultant.

About Altasciences
Altasciences is an integrated drug development solution provider that partners with pharmaceutical and biotechnology companies of all sizes. With over 25 years of experience, Altasciences offers a flexible, one-stop solution for preclinical and clinical study needs, ranging from lead candidate selection to proof of concept. Our services include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all tailored to meet specific sponsor requirements.